Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 50
- Registration Number
- NCT03980171
- Locations
- 🇦🇺
Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
🇦🇺Townsville Hospital and Health Services, Townsville, Queensland, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders
- Conditions
- Interventions
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 10
- Registration Number
- NCT03959358
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL
- Conditions
- Interventions
- First Posted Date
- 2019-05-14
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03949062
- Locations
- 🇨🇳
Ruijin hospital, Shanghai, Shanghai, China
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
- Conditions
- Interventions
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Wuerzburg University Hospital
- Target Recruit Count
- 576
- Registration Number
- NCT03948035
- Locations
- 🇩🇪
Universitätsklinikum Ulm, Ulm, Baden-Wuerttemberg, Germany
🇩🇪Vivantes Klinikum Spandau, Berlin, Germany
🇩🇪Universitätsklinikum Münster, Münster, North Rhine-Westphalia, Germany
Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
- Conditions
- Interventions
- First Posted Date
- 2019-05-08
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1
- Registration Number
- NCT03941860
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States
🇺🇸Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-05-06
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 288
- Registration Number
- NCT03937635
- Locations
- 🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸Doctors Hospital, Columbus, Ohio, United States
🇺🇸West Penn Hospital, Pittsburgh, Pennsylvania, United States
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT03901963
- Locations
- 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸University of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸Arizona Oncology Associates, PC - HAL, Glendale, Arizona, United States
Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL
- Conditions
- Interventions
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 16
- Registration Number
- NCT03891355
- Locations
- 🇮🇹
AOU Senese - U.O.C. Ematologia, Siena, Italy
🇮🇹A.O.U. Citta della Salute e della Scienza di Torino - Ematologia Universitaria, Torino, Italy
🇮🇹Azienda sanitaria-universitaria integrata Trieste (ASUITS) - SC Ematologia, Trieste, Italy
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
- Conditions
- Interventions
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 35
- Registration Number
- NCT03863184
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2019-03-01
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 454
- Registration Number
- NCT03859427
- Locations
- 🇺🇸
Oncology Consultants PA, Houston, Texas, United States
🇳🇱Gelre Ziekenhuizen, Apeldoorn, Netherlands
🇳🇱Spaarne Gasthuis, Hoofddorp, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.